Preventive use of carvedilol for anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials
TD Zhan, MD Daniyal, JD Li, YD Mao - Herz, 2020 - search.proquest.com
Background Clinical or subclinical cardiotoxicity is a concern for cancer patients receiving
anthracycline-based chemotherapy. Carvedilol is promising for preventing anthracycline …
anthracycline-based chemotherapy. Carvedilol is promising for preventing anthracycline …
Cardiotoxicity of non-anthracycline cancer chemotherapy agents
A Briasoulis, A Chasouraki, A Sianis… - Journal of …, 2022 - mdpi.com
Throughout the last decades, newly developed chemotherapeutic agents and
immunotherapies that target signaling pathways have provided patients with better …
immunotherapies that target signaling pathways have provided patients with better …
The Essential Strategies to Mitigate Cardiotoxicity Caused by Doxorubicin
AM Chaulin - Life, 2023 - mdpi.com
The study of mechanisms underlying cardiotoxicity of doxorubicin and the development of
strategies to mitigate doxorubicin-induced cardiotoxicity are the most relevant issues of …
strategies to mitigate doxorubicin-induced cardiotoxicity are the most relevant issues of …
[HTML][HTML] Resveratrol significantly improves cell survival in comparison to dexrazoxane and carvedilol in a h9c2 model of doxorubicin induced cardiotoxicity
DS Monahan, E Flaherty, A Hameed… - Biomedicine & …, 2021 - Elsevier
Cancer is one of the leading causes of deaths worldwide with 18.1 million deaths per year.
Although there have been significant advances in anti-cancer therapies, they can often …
Although there have been significant advances in anti-cancer therapies, they can often …
Protective effect of 23‐hydroxybetulinic acid on doxorubicin‐induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase‐mediated metabolism
F Zhou, G Hao, J Zhang, Y Zheng, X Wu… - British Journal of …, 2015 - Wiley Online Library
Background and Purpose The clinical use of doxorubicin, an effective anticancer drug, is
severely hampered by its cardiotoxicity. 23‐H ydroxybetulinic acid (23‐HBA), isolated from P …
severely hampered by its cardiotoxicity. 23‐H ydroxybetulinic acid (23‐HBA), isolated from P …
[PDF][PDF] Doxorubicin induced cardiomyopathy and its herbal solution
M Garg, T Singhal - International Journal of Pharmaceutical Sciences and …, 2013 - Citeseer
Herbal medicines are represented as the most potential field of alternative medicines all
over the world for a number of diseases in which allopathic medicines have no or little …
over the world for a number of diseases in which allopathic medicines have no or little …
The Prophylactic Effect of Pinocembrin Against Doxorubicin-Induced Cardiotoxicity in an In Vitro H9c2 Cell Model
NF Sangweni, M Moremane, S Riedel… - Frontiers in …, 2020 - frontiersin.org
Background The clinical use of Doxorubicin (Dox) is significantly limited by its dose-
dependent cardiotoxic side effect. Accumulative evidence suggests that the use of …
dependent cardiotoxic side effect. Accumulative evidence suggests that the use of …
Cardiotoxicity associated with Cancer Chemotherapy
MI Jishala, N Venkateswaramurthy… - Research Journal of …, 2020 - indianjournals.com
Based on the World Health Organization (WHO) report, in many of the countries, cancer was
the first or second most cause for death before 70 years of the age. Nowadays cancer …
the first or second most cause for death before 70 years of the age. Nowadays cancer …
Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin
M Lee, WB Chung, J Lee, CS Park, WC Park… - Cancer …, 2021 - Wiley Online Library
Background There is no proven primary preventive strategy for doxorubicin‐induced
subclinical cardiotoxicity (DISC), especially among patients without a cardiovascular (CV) …
subclinical cardiotoxicity (DISC), especially among patients without a cardiovascular (CV) …
[HTML][HTML] Chemotherapy-induced cardiotoxicity: a new perspective on the role of Digoxin, ATG7 activators, Resveratrol, and herbal drugs
HA Al-Hussaniy, AH Alburghaif… - Journal of medicine …, 2023 - ncbi.nlm.nih.gov
Cancer is a major public health problem, and chemotherapy plays a significant role in the
management of neoplastic diseases. However, chemotherapy-induced cardiotoxicity is a …
management of neoplastic diseases. However, chemotherapy-induced cardiotoxicity is a …